Meat Intake and Risk of Stomach and Esophageal Adenocarcinoma Within the European Prospective Investigation Into Cancer and Nutrition (EPIC)

Carlos A. González, Paula Jakszyn, Guillem Pera, Antonio Agudo, Sheila Bingham, Domenico Palli, Pietro Ferrari, Heiner Boeing, Giuseppe del Giudice, Mario Plebani, Fátima Carneiro, Gabriella Nesi, Franco Berrino, Carlotta Sacerdote, Rosario Tumino, Salvatore Panico, Göran Berglund, Henrik Simán, Olof Nyrén, Göran Hallmans, Carmen Martinez, Miren Dorronsoro, Aurelio Barricarte, Carmen Navarro, José R. Quirós, Naomi Allen, Timothy J. Key, Nicholas E. Day, Jakob Linseisen, Gabriele Nagel, Manuela M. Bergmann, Kim Overvad, Majken K. Jensen, Anne Tjonneland, Anja Olsen, H. Bas Bueno-de-Mesquita, Marga Ocke, Petra H. M. Peeters, Mattijs E. Numans, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Antonia Trichopoulou, Theodora Psaltopoulou, Dimitrios Roukos, Eiliv Lund, Bertrand Hemon, Rudolf Kaaks, Teresa Norat, Elio Riboli

The incidences of esophageal adenocarcinoma and gastric cardia cancer have risen steadily in the United States (1) and Europe (2) over the last 3 decades; the incidence of cardia cancer increased less than that of esophageal adenocarcinoma. By contrast, during the same period, the incidences of gastric noncardia cancer and esophageal squamous cell carcinoma declined in most

Affiliations of authors: Department of Epidemiology, Catalan Institute of Oncology, Barcelona, Spain (CAG, PJ, GP, AA); Medical Research Council Dunn Human Nutrition Unit, Cambridge, United Kingdom (SB); Molecular and Nutritional Epidemiology Unit, CSPO-Scientific Institute of Tuscany, Florence, Italy (DP, MMB); German Institute of Human Nutrition, Potsdam-Rehbücke, Germany (HB); IRIS Research Center, Chiron-Vaccines, Siena, Italy (GdG); Servizio di Medicina di Laboratorio, Azienda Ospedaliera di Padova, Padua, Italy (MP); Institute of Molecular Pathology and Immunology of the University of Porto and Medical Faculty, Porto, Portugal (FC); Department of Human Pathology and Oncology, University of Florence, Florence, Italy (G. Nesi); Epidemiology Unit, Istituto Tumori, Milan, Italy (FB); University of Torino, Turin, Italy (CS); Cancer Registry, Azienda Ospedaliera "Civile M.P. Arezzo," Ragusa, Italy (RT); Dipartamento di Medicina Clinica e Sperimentale, Federico II University, Compagnia di San Paolo, Naples, Italy (SP); Department of Medical Epidemiology, Karolinska Instututet, Stockholm, Sweden (GB, HS); Department of Nutritional Research, University of Umeå, Umeå, Sweden (ON, GH); Andalusian School of Public Health, Granada, Spain (CM); Department of Public Health of Guipuzkoa, San Sebastian, Spain (MD); Public Health Institute of Navarra, Pamplona, Spain (AB); Epidemiology Department, Health Council of Murcia, Murcia, Spain (CN); Public Health and Health Planning Directorate, Asturias, Spain (JRQ); Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom (NA, TJK); Strangeways Research Laboratory, Cambridge, United Kingdom (NED); Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany (JL, G. Nagel); Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark (KO, MJK); Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark (AT, AO); Center for Nutrition and Health, National Institute for Public Health and the Environment, Bilthoven, The Netherlands (HBBdM, MO); Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands (PHMP, MEN); INSERM, Institut Gustave Roussy, Villejuif, France (FC-C, M-CB-R); Department of Hygiene and Epidemiology, Medical School, University of Athens, Athens, Greece (AT, TP); University of Ioannina, Medical School, University of Athens, Athens, Greece (DR); Institute of Community Medicine, University of Tromso, Tromso, Norway (EL); Nutrition and Hormones Group, International Agency for Research on Cancer, Lyon, France (PF, BH, RK, TN, ER).

Correspondence to: Carlos A. González, MD, PhD, Department of Epidemiology, Catalan Institute of Oncology, Barcelona, Spain (e-mail: cagonzalez@ico.scs.es). *See* "Notes" following "References." countries (3). Overall, gastric and esophageal cancers are the second and sixth most common causes of cancer death in the world, respectively (3).

These similar incidence trends suggest that esophageal adenocarcinoma and gastric cardia cancer share, at least in part, some etiologic factors despite their epidemiologic differences (4). Gastric cardia cancer and esophageal adenocarcinoma are associated with gastroesophageal reflux disease, Barrett's esophagus, and obesity (5). Infection with *Helicobacter pylori* is an established risk factor for gastric noncardia cancer but not for gastric cardia cancer (6), and *H. pylori* infection has been associated with a reduced risk of esophageal adenocarcinoma (7). Tobacco smoking is causally associated with cardia and gastric noncardia cancer (8) and with both types (i.e., adenocarcinoma and squamous cell carcinoma) of esophageal cancer (9). Dietary factors are also thought to have an important role in gastric and esophageal carcinogenesis, but evidence from cohort studies for such a role, particularly among Western populations, is lacking.

Meat consumption is a dietary factor that has been linked to several cancers. High meat consumption has been associated with increased risks of colorectal cancer (10), breast cancer (11) and, possibly, prostate cancer (12). However, a comprehensive review on nutrition and cancer published in 1997 (13) concluded that there was insufficient evidence that total meat consumption or consumption of cured meat was related to the risk of gastric cancer and that judgment about associations with the risk of esophageal cancer was not possible because the evidence was limited. Since then, several new cohort studies on dietary factors and the risk of gastric cancer have contributed to the available evidence, all showing either no association (14,15) or a weak but nonstatistically significant association (16) between total meat, beef, or pork intake and the risk of gastric cancer. Processed meat intake was statistically significant and positively associated with the risk of gastric cancer in two cohort studies (15,17) but not in three other studies (14,18,19), and none of the studies took into account the anatomical site of the cancer (gastric cardia cancer versus gastric noncardia cancer). Associations between intakes of meat and processed meat and the risk of esophageal cancer have not yet been analyzed in a cohort study among a Western population.

The goal of this study was to examine associations between meat and processed meat intake and the risks of stomach and esophageal adenocarcinomas within the European Prospective Investigation Into Cancer and Nutrition (EPIC) (20), a large prospective cohort that includes participants with large differences in meat consumption (21). Furthermore, we examined, for the first time, whether *H. pylori* infection modifies these associations by conducting a nested case–control study within the EPIC cohort.

SUBJECTS AND METHODS

Study Subjects

EPIC, a prospective study that has been described in detail elsewhere (20,22), was designed to investigate the relationships between dietary, lifestyle, genetic, and environmental factors and the incidence of cancer. EPIC cohorts are recruited through 23 research centers located in 10 European countries: Denmark (Aarhus, Copenhagen), France, Germany (Heidelberg, Potsdam), Greece, Italy (Florence, Turin, Varese, Naples, Ragusa), The Netherlands (Bilthoven, Utrecht), Norway, Spain (Granada, Murcia, Asturias, Navarra, San Sebastian), Sweden (Malmo, Umeå), and the United Kingdom (Norfolk, Oxford). The EPIC cohorts include a total of 521457 subjects (368010 women and 153 447 men), most of whom were recruited between 1992 and 1998 when they were 35-70 years old, usually from the general population residing in a given geographic area, town, or province. Exceptions were the French cohort, in which participants were recruited from among female members of the health insurance agency for school employees; the Utrecht and Florence cohorts, in which participants were recruited from among women attending breast cancer screening programs; parts of the Italian and Spanish cohorts, in which participants were recruited from among blood donors; and most of the Oxford cohort, in which participants were recruited from among vegetarian volunteers. Blood samples (30 mL) were collected from approximately 74% of the EPIC participants. After extraction, blood samples were aliquoted into plastic straws of serum, plasma, white blood cells, and erythrocytes and stored in liquid nitrogen (at -196 °C) in a central repository. Eligible participants gave written informed consent and completed questionnaires on their diet, lifestyle, and medical history. Approval for this study was obtained from the ethical review boards of the International Agency for Research on Cancer (IARC) and from all local participating centers.

We excluded from this study prevalent cancer cases (138 gastric cancers and 22 esophageal adenocarcinomas) and 2403 subjects who were lost to follow-up, as well as all subjects in the Norway cohort because of the small number of incident cases (two gastric cancer cases from among 37203 subjects at risk) and the short follow-up.

Diet and Lifestyle Questionnaires

The usual diet over the previous 12 months was measured at EPIC study recruitment with the use of country-specific validated questionnaires (20,23). Most centers adopted a self-administered dietary questionnaire that included 88-266 food items. In Greece, Spain, and Ragusa, the dietary questionnaire was administered at a personal interview. Dietary questionnaires in France, Northern Italy, Spain, The Netherlands, Germany, and Greece were quantitative, estimating individual average portion size. Those in Denmark, Naples, and Umeå were semiquantitative, with the same standard portion size assigned to all participants. In Malmö and the United Kingdom, diet was measured by a dietary questionnaire combined with a food record. A separate lifestyle questionnaire included questions on education level, lifetime history of smoking and alcohol consumption, occupation, reproductive history, use of hormones, history of previous illness including surgical operations, and physical activity level.

Follow-Up and Identification of Cancer Cases

The follow-up was based on information in population cancer registries, except in France, Germany Greece, and Naples, where a combination of methods including health insurance records, cancer and pathology hospital registries, and active follow-up were used. Mortality data were collected from regional or national mortality registries. Follow-up began on the date of EPIC recruitment and ended on the date of diagnosis of gastric or esophageal cancer, the date of death, or date of the last complete follow-up, whichever came first. A total of 398 incident gastric cancer cases and 188 incident esophageal cancer cases were reported to the central database at IARC for the period up to December 31, 1999 or September 30, 2002, depending on the study center. Cancer of the stomach included cancers coded as C16 according to the 10th Revision of the International Statistical Classification of Diseases, Injuries and Causes of Death (24). Validation and confirmation of the diagnosis and classification of tumor site and of tumor morphology [according to International Classification of Diseases for Oncology, 2nd version, and Lauren classification of histologic type (25)] were carried out by a panel of pathologists that included a representative from each country participating in EPIC and a coordinator (FC). The panel reviewed material provided by the centers (original histology slides and/or slices obtained from paraffin blocks of tumor specimens as well as the original pathology reports). Among incident cancer cases, we excluded nonadenocarcinomas of the esophagus (n = 121), gastric lymphomas (n = 26), gastric stump cancers (n = 5), other nonadenocarcinoma gastric cancers (n = 11), and otherwise unspecified malignant neoplasms of the stomach (n = 8). After these exclusions, 348 gastric adenocarcinoma cases and 67 esophageal adenocarcinoma cases were available for the analysis. Of these cases, 56% (n = 195) were validated by a panel of pathologists through review of the available histologic material, 24% (n = 83) were classified according to the pathology report, and 20% (n = 70) were classified on the basis of information reported by the cancer registries to the IARC central database. Gastric cardia tumors included gastroesophageal junction tumors (n = 24).

Nested Case-Control Study of H. pylori Infection Status

We conducted a nested case–control study within the EPIC cohort to examine whether the association between meat intake and cancer risk was modified by *H. pylori* infection. Each case subject with incident gastric cancer and an available blood sample was matched by sex, age group (± 2.5 years), center, and date of blood sample collection (± 45 days) to four control subjects with available blood samples who were randomly selected from among subjects in the cohort still at risk at the time of diagnosis of each case.

The concentration of anti-H. pylori immunoglobulin G (IgG) antibodies was measured by an enzyme-linked immunosorbent assay. Briefly, dilutions of plasma samples (from 1:200 to 1:25 600) were incubated for 1 hour in 96-well flat-bottomed microtiter plates (Nunc, Roskilde, Denmark) coated with a wholecell lysate of H. pylori [CCUG strain (26)] (1 µg/mL). The wells were washed extensively and incubated for 3 hours with an alkaline phosphatase-conjugated affinity-purified polyclonal goat anti-human IgG (Sigma Chemical Co, St. Louis, MO). After further washings, the presence of bound human IgG antibodies specific for H. pylori was detected by adding 1 mg/mL p-nitrophenylphosphate (100 µL/well) to the plates. Optical densities were read after 1 hour at 405 and 650 nm. H. pylori-specific IgG antibody titers were expressed as arbitrary enzyme-linked immunosorbent assay units (EU) and were determined by interpolation relative to a standard curve constructed by serial dilutions of a standard positive control consisting of a pool of samples from subjects known to be infected with H. pylori and to have antibodies, as determined by Western blotting. A cutoff value of 100 EU was defined using serum samples from individuals negative for H. pylori infection as determined by clinical, microbiologic, and serologic (western blotting) assays. Serum samples giving EU values above 100 were considered positive for anti-H. pylori IgG antibodies.

Calibration of the Dietary Data

We used a detailed computerized 24-hour diet recall (24HR) method (27) to obtain a second dietary measurement (between 1995 and 1999) from a random sample of the cohort (7.1% of total cohort; $n = 36\,994$ participants) to calibrate dietary measurements across countries and to correct for systematic over- or underestimation of dietary intakes (28,29). Country- and sex-specific calibration models were used to obtain individual predicted values of dietary exposure for all participants. Calibration models were used for meat intake (total, red, processed, and poultry), total vegetable intake, non-citrus fresh fruit intake, citrus intake, and energy. The 24HR values were regressed on the intake values for meat (total, red, processed, and poultry), total vegetables, non-citrus fresh fruit, and fresh citrus fruit and the values for energy obtained from the main dietary questionnaires. Consumption values of zero in the main dietary questionnaires (reported by 0% to 13% of the participants, depending on the food variable) were excluded from the regression calibration models; instead, a zero was directly imputed as the corrected value. Weight, height, age at study recruitment, and study center were included as additional covariates, and data were weighted by the day of the week and the season of the year in which the 24HR diet recall data were collected. Cox regression models were then run using the predicted (calibrated) values of the meat variable of interest and the calibrated values of the adjusting variables (total vegetables, non-citrus fresh fruit, citrus, and energy) for each individual on a continuous scale, and the other adjusting variables used in the noncalibrated model. The standard error of the deattenuated coefficient was calculated with bootstrap sampling in the calibration and disease models consecutively (29).

Statistical Methods

Analyses were conducted using Cox regression. We confirmed the proportional hazards assumption for meat intake variables in relation to gastric and esophageal adenocarcinomas using the likelihood ratio test, comparing models with and without product terms for the meat variables and follow-up time (years). Data were stratified by study center and age at EPIC study recruitment to control for differences in follow-up procedures and questionnaire design. Age at EPIC study recruitment was used as the time scale variable in all models. Entry time was defined as age at recruitment, and final time was defined as the age at diagnosis for case patients or the age at censoring for at-risk subjects. All models were adjusted for sex, height, weight, educational level, alcohol intake (grams/day) at baseline, smoking status (never, former, or current), number of cigarettes smoked per day (in current smokers only), level of work-related physical activity (no activity, sedentary, standing, manual, or heavy manual), level of leisure-time physical activity (as continuous metabolic equivalents for the energy expended-hour/week), energy intake (Kcal/ day), and consumption of total vegetables, non-citrus fresh fruit, and citrus fruit (grams/day). Intakes of total meat, red meat, poultry, and processed meat were estimated, in grams per day, from information reported in the dietary questionnaires. Red meat, poultry, and processed meat intakes were mutually adjusted for in the models. Red meat intake included pork, beef, veal, and lamb. Poultry intake included chicken, turkey, and duck. Processed meat intake included ham, bacon, sausages, processed meat cuts, hamburgers (i.e., beef burgers), meatballs, and pâtés

(21). Intakes were analyzed as continuous variables (per 100-g increase for total meat intake, per 50-g increase for red and processed meat intakes, and per 10-g increase for poultry intake) and as categorical variables using EPIC study-wide sex-specific quartiles for analyses of associations with gastric cancer risk and tertiles for analyses of associations with esophageal adenocarcinoma risk. To calculate P values for trends across quartiles (or tertiles), participants were assigned a score ranging from 1 to 4 (or 1 to 3) according to their quartile (or tertile) of intake and this variable was entered as a continuous term in the Cox regression models. Separate analyses were done for men and women, but because no substantial differences by sex emerged, we present the results for both sexes combined in this report. Subsequent analyses were performed after exclusion of case patients who were diagnosed during the first 2 years of follow-up. The Wald statistic (30) was used to test for homogeneity of risk for cardia and gastric noncardia tumors.

The odds ratio (OR) for association of meat and processed meat intake in *H. pylori* antibody-positive and -negative subjects in the nested case–control study was estimated by multiple unconditional logistic regression, including matching variables in the model. The statistical significance of interactions between intakes of different meat variables and *H. pylori* infection were assessed using a likelihood ratio test. All statistical tests were two-sided, and *P* values less than .05 were considered statistically significant.

RESULTS

During a mean follow-up of 6.5 years (3110034 person-years) starting in 1991, 348 eligible stomach adenocarcinomas and 67 esophageal adenocarcinomas were diagnosed (Table 1). The stomach adenocarcinomas included 101 cancers in the gastric cardia (24 of which were in the gastroesophageal junction), 166 cancers in the distal part of the stomach, and 81 cancers (23%) of unknown location. According to Lauren classification (25), 116 gastric cancers (33.3%) were intestinal, 120 (34.5%) were diffuse, four (1.1%) were mixed, and 108 (31.0%) were unclassified or unknown. We excluded from the analyses individuals who were in the top or bottom 1% of energy intake (31) (seven subjects with gastric cancer, one subject with esophageal adenocarcinoma, and 9426 members of the cohort) and individuals with missing dietary information (11 subjects with gastric cancer, one subject with esophageal adenocarcinoma, and 6486 members of the cohort). The final sample for analyses included 330 gastric cancer patients (56% of whom were men) and 65 esophagus adenocarcinoma patients (77% of whom were men). A total of 241 gastric cancer patients with available blood samples and 1141 matched control subjects were included in the nested case-control study. Table 1 also shows the mean intakes of red meat, processed meat, and poultry by country, which were estimated using the 24HR data collected in the calibration study. Processed meat consumption varied between countries by approximately 10-fold, and red meat consumption varied by two- to threefold.

Baseline characteristics of the participants according to meat intake levels are reported in Table 2. Subjects with the highest intake of red meat were more likely to have ever smoked than subjects with the lowest intake of red meat, and subjects with the highest intake of processed meat had lower intakes of citrus and non-citrus fruits and vegetables than subjects with the lowest intake of processed meat. Table 3 shows the mean intake levels of red meat, processed meat, and poultry within each study-wide quartile of intake. For both men and women, the mean intake of red meat in the highest intake quartile was more than twofold higher than that in the lowest intake quartile. For men, the mean intake of processed meat in the highest intake quartile was 4.5 times higher than that in the lowest intake quartile, and for women, it was 3.5 times higher.

Table 4 shows the hazard ratios (HRs) for risks of gastric cancer and esophageal adenocarcinoma associated with total meat intake. In the observed uncalibrated analysis, there was a statistically significant positive association between total meat intake and the risk of gastric cancer ($P_{\text{trend}} = .01$). The calibrated hazard ratio for a 100-g/day increase in intake was 2.03 (95% CI = 1.28 to 3.22). The positive association between total meat intake and the risk of gastric cancer was restricted to gastric noncardia cancers (calibrated HR for a 100-g/day increase in intake = 3.52; 95% CI = 1.96 to 6.34); there was no association between total meat intake and the risk of cardia cancer (P for heterogeneity = .01). No differences between the hazard ratios of intestinal and diffuse types for total meat intakes were observed. We also observed a non-statistically significant positive association between total meat intake and the risk of esophageal adenocarcinoma for the whole cohort (calibrated HR for a 100-g/day increase in intake = 1.84; 95% CI = 0.78 to 4.39). In the uncalibrated model, we observed a positive association of borderline statistical significance between red meat intake and gastric cancer risk for the highest level of consumption ($P_{\text{trend}} = .05$); the calibrated hazard ratio was not statistically significant. This positive association between red meat intake and gastric cancer risk was restricted to noncardia tumors (calibrated HR for a 50-g/day increase in intake = 1.73; 95% CI = 1.03 to 2.88; *P* for heterogeneity = .19). A non-statistically significant positive association between red meat intake and esophageal adenocarcinoma was observed in the uncalibrated model, but not in the calibrated model.

We observed a statistically significant positive association between poultry consumption and the risk of gastric cancer for the highest category of intake in the uncalibrated analysis (Table 4). However, this association disappeared in the calibrated model. We also observed a statistically significant positive association between poultry intake and esophageal adenocarcinoma (calibrated HR for a 10-g/day increase in intake = 1.14; 95% CI = 1.00to 1.30). We found a statistically significant positive association between processed meat intake and gastric cancer risk ($P_{\text{trend}} =$.02), with a 62% increase in risk for the highest versus the lowest quartile of intake. This association between processed meat and the risk of gastric cancer was observed only for noncardia tumors (calibrated HR for a 50-g/day increase in intake = 2.45; 95% CI = 1.43 to 4.21; P for heterogeneity = .02). Processed meat intake was also positively associated with the risk of esophageal adenocarcinoma (HR for the highest versus the lowest tertile of intake = 3.54; 95% CI = 1.57 to 7.99; P_{trend} = .002), but the association was not statistically significant in the calibrated model. In this study population, the absolute risk of development of gastric adenocarcinoma within 10 years for a study subject aged 60 years was 0.26% for the lowest quartile of total meat intake and 0.33% for the highest quartile of total meat intake.

To eliminate the potential effects of early undiagnosed gastric or esophageal cancers, we repeated our analyses after excluding case patients whose cancers were diagnosed during the 2 first years of follow-up because these individuals might have

) cohort*	
on (EPIC	
d Nutriti	
ancer an	
on Into C	
vestigatio	
ective In	
an Prosp	
Europe:	
ing in the	
articipat	
ountries p	
ŭ.	
Table 1	

	ssed meat	Women	28.8 (46.4)) 21.0 (36.3)	0 30.5 (44.2)) 18.1 (38.0)) 37.4 (51.1)	5.0 (21.4)) 42.5 (55.7)) 42.1 (53.1)) 24.5 (39.0)) 30.4 (47.1	
	Proce	Men	N/A	33.2 (51.9	54.2 (68.6	30.0 (55.1	76.7 (85.7	8.4 (32.2	84.7 (89.9	64.0 (77.1	51.6 (64.2	55.1 (74.4	
	ltry	Women	24.3 (51.5)	24.2 (58.7)	27.1 (55.8)	18.8 (48.8)	13.7 (39.7)	11.6 (37.2)	13.1 (42.1)	9.2 (32.8)	15.6 (42.0)	17.6 (46.3)	
IILAKE (B'U)	Pot	Men	N/A	35.6 (72.0)	37.5 (80.0)	22.8 (53.2)	18.2 (53.8)	16.0(44.9)	17.0 (55.9)	10.0 (39.2)	17.4 (50.5)	20.6 (57.5)	
י ליווויה (תה) ו	neat	Women	46.1 (68.2)	38.5 (64.2)	37.9 (67.7)	19.3 (44.3)	40.1 (55.1)	26.9 (53.0)	29.6 (56.6)	34.9 (54.3)	43.2 (58.1)	37.9 (60.4)	
IDATAT	Red n	Men	N/A	58.5 (90.7)	85.5 (123.4)	33.0 (70.7)	64.9 (90.4)	46.8 (80.9)	51.7 (87.7)	53.6 (75.5)	69.2 (83.8)	59.8 (90.6)	
	neat	Women	104.5 (85.4)	86.9 (85.2)	99.9 (91.7)	57.4 (70.2)	92.0 (73.6)	45.5 (67.3)	86.6 (81.4)	90.0 (72.8)	85.2 (69.5)	88.9 (80.2)	
	Total m	Men	N/A	132.6 (112.1)	184.5 (149.0)	87.1 (99.1)	160.9 (127.3)	76.5 (99.5)	155.8 (124.1)	134.4 (99.4)	140.4 (96.2)	139.8 (118.9)	
	Esophageal	adenocarcinoma	0	2	0	25	4	0	2	13	21	67	
		Diffuse§	б	16	13	6	12	6	23	27	8	120	
	cinoma‡	Intestinal§	ю	26	13	13	9	4	15	23	13	116	
	ch adenocar	Noncardia	4	31	21	23	6	4	24	34	16	166	
	Stoma	Cardia§	4	8	9	21	6	7	10	17	24	101	
		Gastric§	11	52	32	52	29	16	44	59	53	348	
	Person-	years	625 111	280660	276962	466048	249585	100514	309303	419150	382701	3 110034	
	Cohort	sample	74504	47531	41413	87352	40047	26856	53030	53769	57016	481518	
		Country	France	Italy	Spain	United Kingdom	The Netherlands	Greece	Germany	Sweden	Denmark	Total	

(Cambridge, Oxford [general and health-conscious population]); The Netherlands (Bilthoven, Utrecht); Germany (Heidelberg, Potsdam); Sweden (Malmö, Umeå); Denmark (Aarhus, Copenhagen). SD = standard deviation; N/A = not applicable. *Study centers per country: France (North-East, North-West, South, South coast); Italy (Florence, Varese, Ragusa, Turin, Naples); Spain (Asturias, Granada, Murcia, Navarra, San Sebastian), United Kingdom

†Based on the 24-hour recall dietary questionnaire of the calibration study participants (13437 men and 21674 women).

 \pm Excludes nonadenocarcinoma gastric cancers (n = 45) and gastric stump cancers (n = 5).

 $\frac{1}{2}$ Sincludes gastroscophageal junction tumors. Cardia and noncardia classifications do not include tumors of unknown (n = 75) or mixed (n = 6) locations. Intestinal and diffuse classifications do not include unknown (n = 94), unclassified (n = 14), or mixed (n = 4) morphologies.

|Only women.

	×.
1	÷
	õ
	Ξ
,	3
	õ
	ŝ
	8
	õ
	ā
	σ
	Ē
	~
	⊵
÷	=
	2
	ă
	Ĵ.
	g
	ğ.
	-
	8
,	Ξ.
1	5
	õ
	Ξ.
	153
	Η
<	H
	~
	S
÷	Ξ
	H
	ä.
	σ
	5
	bn
	đ
÷	Ð
	Ы
	స్ట
	ac
,	5
	ŭ
	g
÷	Ę
	I.c
	S
	6
	t
	õ
	R
	5
4	-
- 2	2
ŝ	2
ļ	T)
1	
	5
1	Ĕ
1	Ξ
	Ξ
7	Z
	d D
	_
	н
	r ar
	cer ar
	ncer ar
,	ancer ar
(Cancer ar
(to Cancer ar
(Into Cancer ar
(n Into Cancer ar
(on Into Cancer ar
(, ,	ation Into Cancer ar
(gation Into Cancer ar
(, , , , , , , , , , , , , , , , , , ,	tigation Into Cancer ar
(estigation Into Cancer ar
() 	ivestigation into Cancer ar
	Investigation Into Cancer ar
	e Investigation Into Cancer ar
	ive Investigation Into Cancer ar
	ctive Investigation Into Cancer ar
	bective Investigation Into Cancer ar
	spective investigation into Cancer ar
	rospective investigation into Cancer ar
	Prospective Investigation Into Cancer ar
() , , , , , , , , , , , , , , , , , , ,	n Prospective Investigation Into Cancer ar
() , , , ,	ean Prospective Investigation Into Cancer ar
	pean Prospective Investigation Into Cancer ar
() , , ,	ropean Prospective Investigation Into Cancer ar
(, , , , , , , , , , , , , , , , , , ,	uropean Prospective Investigation Into Cancer ar
	European Prospective Investigation Into Cancer ar
	ne European Prospective Investigation Into Cancer ar
	the European Prospective Investigation Into Cancer ar
	in the European Prospective Investigation Into Cancer ar
	s in the European Prospective Investigation Into Cancer ar
	nts in the European Prospective Investigation Into Cancer ar
	vants in the European Prospective Investigation Into Cancer ar
	upants in the European Prospective Investigation Into Cancer ar
	acipants in the European Prospective Investigation Into Cancer ar
	irticipants in the European Prospective Investigation Into Cancer ar
	participants in the European Prospective Investigation Into Cancer ar
	e participants in the European Prospective Investigation Into Cancer ar
	the participants in the European Prospective Investigation Into Cancer ar
	If the participants in the European Prospective Investigation Into Cancer ar
	of the participants in the European Prospective Investigation Into Cancer ar
	cs of the participants in the European Prospective Investigation Into Cancer ar
	tics of the participants in the European Prospective Investigation Into Cancer ar
	ristics of the participants in the European Prospective Investigation Into Cancer ar
	eristics of the participants in the European Prospective Investigation Into Cancer ar
	cteristics of the participants in the European Prospective Investigation Into Cancer ar
	racteristics of the participants in the European Prospective Investigation Into Cancer ar
	haracteristics of the participants in the European Prospective Investigation Into Cancer ar
	characteristics of the participants in the European Prospective Investigation Into Cancer ar
	e characteristics of the participants in the European Prospective Investigation Into Cancer ar
	ine characteristics of the participants in the European Prospective Investigation Into Cancer ar
	eline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	aseline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	Baseline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	. Baseline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	Baseline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	e 2. Baseline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	ble 2. Baseline characteristics of the participants in the European Prospective Investigation Into Cancer ar
	able 2. Baseline characteristics of the participants in the European Prospective Investigation Into Cancer ar

		Red	meat intake, g/d		Pou	ltry intake, g/d		Processed	d meat intake, g/d	
Characteristic	Whole cohort $(n = 465586)$	Quartile 1 [M: $0-26$, W: $0-17$] [$n = 116534$)	Quartile 4 [M: 84–1087, W: 61–584] (<i>n</i> = 116 399)	b‡	Quartile 1 M: $0-7$ M, W: $0-5$] (n = 116396)	Quartile 4 [M: 29–690, W: 26–690] (n = 116398)	Þ;	Quartile 1 [M: 0–16, W: 0–9] [N (n = 116355)	Quartile 4 1: 59–731, W: 37–771] (n = 116396)	P^{+}_{+}
Mean age, years (SD) Median alcohol intake, g/d	51.7 (10.2) 6.0 (0–339)	49.4 (12.1) 4.7 (0–339)	52.4 (8.8) 8.7 (0–298)	<.001 <.001	50.4 (11.8) 5.6 (0–339)	52.0 (9.3) 6.4 (0–310)	<.001 <.001	50.4 (12.6) 4.1 (0–310)	51.3 (9.1) 7.5 (0–339)	<.001 <.001
(range) Mean BMI, kg/m ² (SD) Ever tobacco smoker. %	25.5 (4.3) 49.2	24.5 (4.1) 44.7	25.9 (4.4) 53.5	<.001	24.5 (4.0) 49.3	26.2 (4.5) 47.3	<.001 <.001	25.2 (4.5) 44.9	25.9 (4.4) 51.6	<.001 <.001
Secondary school education or higher %	48.9	57.5	46.3	<.001	54.8	47.1	<.001	52.7	44.6	<.001
Mean leisure physical activity, MET-h/wk (SD)	82.7 (49.6)	84.2 (48.7)	79.1 (49.8)	<.001	79.8 (47.6)	82.5 (50.9)	<.001	86.1 (50.5)	81.7 (48.5)	<.001
Perform manual activity at work, %	11.8	0.0	15.1	<.001	9.8	11.2	<.001	10.5	11.7	<.001
Mean energy intake, Kcal/day (SU) Mean total vegetable intake,	2136 (632) 217 (149)	1909 (576) 222 (160)	2411 (652) 230 (147)	<.001 <.001	2010(609) 207(153)	2310 (656) 262 (153)	<.001 <.001	1937 (575) 290 (188)	2404 (6/4) 187 (121)	<.001
g/d (SD) Mean non-citrus fresh fruit intake,	191 (153)	194 (162)	187 (149)	<.001	181 (153)	219 (161)	<.001	246 (188)	163 (126)	<.001
gu (DD) Mean citrus fruit intake, g/d (SD)	54.7 (72.7)	47.1 (69.5)	54.1 (68.3)	<.001	41.0 (59.2)	69.0 (84.2)	<.001	73.8 (92.2)	43.0 (59.9)	<.001
*Intakes determined from EPIC d	ietary questionn	iaire data. M = range o	f intake among men, $W = 1$	range of	intake among womer	I; SD = standard deviation	n; BMI =	= body mass index; MI	ET = metabolic equivaler	nts for

†For continuous variables, two-sided t tests and Wilcoxon tests were used. For categorical variables, two-sided chi-square tests were used. allgo the energy expended (ratio of physical activity metabolic rate to a standard metabolic rate of 1).

			Men			W	omen	
Type of meat	Quartile 1	Quartile 2	Quartile 3	Quartile 4	Quartile 1	Quartile 2	Quartile 3	Quartile 4
Total meat	91.0 (0-78)	127.4 (78–119)	152.3 (119–166)	186.7 (166–1196)	60.5 (0-53)	79.7 (53–86)	94.0 (86–121)	117.9 (121–929)
Red meat Poultry	34.3 (0–26) 10.2 (0–7)	51.5 (26–52) 15.5 (7–16)	66.5 (52–84) 21.9 (16–29)	84.6 (84–1087) 34.0 (29–690)	22.6 (0–17) 11.6 (0–5)	31.2 (17–36) 13.4 (5–14)	40.6 (36–61) 18.7 (14–26)	52.9 (61–584) 27.2 (26–690)
Processed meat	19.1 (0–16)	46.9 (16–34)	64.8 (34–59)	85.6 (59–731)	13.1 (0–9)	25.8 (9–20)	34.4 (20–37)	45.4 (37–771)

Table 3. Mean intake (range) of total meat, red meat, poultry, and processed meat according to sex-specific study-wide quartiles in the European Prospective Investigation Into Cancer and Nutrition (EPIC) cohort*

*Mean intake reported as g/day. Ranges are based on values reported on the food questionnaires, and the means were estimated from the 24-hour dietary recall data from the calibration study.

modified their diet during the early, prediagnostic phase of the disease. None of our findings for associations between red meat, processed meat, or poultry and the risk of either gastric cancer or esophageal adenocarcinoma changed after we excluded these case patients. In addition, although the number of cancer cases was small, after stratifying the sample by Northern versus Southern European countries (data not shown) the results were very similar. We also examined associations with different subgroups of red and processed meat, but we did not find that a particular type of either red meat or processed meat was more strongly associated with gastric cancer than other types. Intakes of red and processed meat were highly correlated (Pearson's r = .65), whereas the correlation between intakes of processed meat and poultry was very low (Pearson's r = .05), and the correlation between intakes of red meat and poultry was moderate (Pearson's r = .23).

Finally, we conducted a nested case–control study to examine whether *H. pylori* infection (as assessed by plasma level of antibodies against *H. pylori*) modified the associations between total meat, red meat, poultry, or processed meat intakes and the risk of gastric cancer (Table 5). We observed a statistically significant

Table 4. Multivariable hazard ratio (HR) of stomach and esophageal adenocarcinoma (95% confidence intervals) for observed and calibrated intakes of total meat, red meat, poultry, and processed meat according to anatomic location and histologic type of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC) cohort*

Cancer site/type			Observed quartiles/	'tertiles†		Contin	nuous
and type of meat	No. of cases	2	3	4	Ptrend	Observed	Calibrated
Stomach	330						
Total meat		1.05 (0.75 to 1.49)	1.59 (1.12 to 2.24)	1.50 (1.01 to 2.23)	.01	1.30 (1.05 to 1.62)	2.03 (1.28 to 3.22)
Red meat		1.22 (0.87 to 1.71)	1.27 (0.89 to 1.82)	1.50 (1.02 to 2.22)	.05	1.14 (0.97 to 1.33)	1.31 (0.89 to 1.94)
Poultry		1.29 (0.93 to 1.80)	1.30 (0.92 to 1.83)	1.47 (1.04 to 2.10)	.04	1.01 (0.96 to 1.07)	0.95 (0.81 to 1.13)
Processed meat		1.10 (0.76 to 1.58)	1.16 (0.79 to 1.69)	1.62 (1.08 to 2.41)	.02	1.18(0.97 to 1.43)	1.64 (1.07 to 2.51)
Cardia	94	· · · · ·	· · · · ·	· · · · ·		· · · · ·	,
Total meat		0.82 (0.43 to 1.57)	1.15 (0.60 to 2.19)	1.00 (0.48 to 2.08)	.75	0.95 (0.63 to 1.43)	0.84 (0.31 to 2.28)
Red meat		1.56 (0.80 to 3.02)	1.48 (0.73 to 3.02)	1.17 (0.53 to 2.60)	.85	1.04 (0.79 to 1.38)	1.09 (0.46 to 2.59)
Poultry		1.37 (0.72 to 2.61)	1.67 (0.88 to 3.19)	1.57 (0.80 to 3.09)	.16	0.96 (0.86 to 1.08)	0.82 (0.60 to 1.14)
Processed meat		1.19 (0.61 to 2.34)	1.04(0.51 to 2.12)	1.14 (0.52 to 2.49)	.91	0.89 (0.59 to 1.34)	0.76 (0.29 to 1.96)
Noncardia	159	· · · · ·	· · · · ·	· · · · ·		· · · · ·	,
Total meat		1.49 (0.89 to 2.48)	1.95 (1.15 to 3.30)	2.19 (1.22 to 3.93)	.01	1.67 (1.25 to 2.24)	3.52 (1.96 to 6.34)
Red meat		0.90 (0.56 to 1.44)	1.29 (0.79 to 2.10)	1.65 (0.97 to 2.82)	.03	1.30 (1.04 to 1.63)	1.73 (1.03 to 2.88)
Poultry		1.17(0.71 to 1.94)	1.51 (0.92 to 2.46)	1.65(1.00 to 2.74)	.03	1.03 (0.96 to 1.11)	1.01(0.81 to 1.27)
Processed meat		1.02 (0.60 to 1.71)	1.02 (0.59 to 1.77)	1.92 (1.11 to 3.33)	.01	1.36 (1.06 to 1.74)	2.45 (1.43 to 4.21)
Intestinal	109	· · · · ·	· · · · ·	· · · · ·		· · · · ·	,
Total meat		1.05 (0.59 to 1.87)	1.49 (0.82 to 2.70)	1.24 (0.61 to 2.51)	.33	1.31 (0.90 to 1.92)	2.14 (0.87 to 5.23)
Red meat		1.29 (0.73 to 2.30)	1.52 (0.83 to 2.78)	1.23 (0.61 to 2.51)	.46	1.03 (0.76 to 1.40)	1.10 (0.50 to 2.44)
Poultry		1.02 (0.57 to 1.80)	1.06 (0.58 to 1.93)	1.46 (0.81 to 2.62)	.21	1.03 (0.93 to 1.13)	0.94 (0.70 to 1.27)
Processed meat		1.62(0.84 to 3.11)	1.67 (0.84 to 3.33)	1.78 (0.84 to 3.77)	.18	1.27 (0.93 to 1.75)	2.11(1.08 to 4.14)
Diffuse	116	()	()			((,
Total meat		0.80 (0.44 to 1.46)	1.76 (1.00 to 3.07)	1.34 (0.69 to 2.58)	.09	1.23 (0.85 to 1.80)	1.52 (0.67 to 3.43)
Red meat		1.11 (0.65 to 1.91)	0.95 (0.51 to 1.75)	1.74 (0.93 to 3.24)	.13	1.13 (0.84 to 1.51)	1.10 (0.54 to 2.23)
Poultry		1.33 (0.76 to 2.34)	1.50 (0.84 to 2.67)	1.87 (1.05 to 3.33)	.03	1.05 (0.97 to 1.14)	1.04 (0.78 to 1.39)
Processed meat		0.75 (0.39 to 1.45)	0.88 (0.45 to 1.70)	1.47 (0.76 to 2.82)	.10	1.04 (0.75 to 1.43)	1.40 (0.69 to 2.85)
Esophagus	65			(((
Total meat		0.96 (0.48 to 1.93)	1.79 (0.86 to 3.75)	N/A	.10	1.56 (1.11 to 2.19)	1.84 (0.78 to 4.39)
Red meat		1.73 (0.86 to 3.48)	1.67 (0.75 to 3.72)		.23	1.13 (0.84 to 1.51)	0.75 (0.26 to 2.13)
Poultry		1.29 (0.67 to 2.49)	1.93 (0.99 to 3.76)		.05	1.12 (1.06 to 1.20)	1.14 (1.00 to 1.30)
Processed meat		2.08 (0.96 to 4.47)	3.54 (1.57 to 7.99)		.002	1.16 (0.82 to 1.65)	1.44 (0.64 to 3.22)

*Reference categories are the lowest quartile and tertile for quartile and tertile analyses, respectively. For continuous analysis, HRs are for a daily intake increase of 100 g (total meat), 50 g (red and processed meat), or 10 g (poultry). The full-cohort analysis was stratified by center and age at EPIC study entry and adjusted by sex, height, weight, education level, tobacco smoking, cigarette smoking intensity, work and leisure physical activity, alcohol intake, energy intake, vegetable intake, citrus fruit intake. Red meat, poultry, and processed meat intakes were mutually adjusted. N/A = not applicable.

[†]For esophageal cancer, tertiles were used instead of quartiles because of the small sample size. The cutoff points for the total meat tertiles, in grams/day, were (men/women): 92.64/64.56 and 148.88/107.96. The cutoff points for the red meat tertiles, in grams/day, were (men/women): 34.15/22.98 and 72.61/51.18. The cutoff points for the poultry tertiles, in grams/day, were (men/women): 9.13/7.50 and 21.98/20.35. The cutoff points for the processed meat tertiles, in grams/day, were (men/women): 21.58/12.60 and 49.15/30.48. Quartiles and tertiles are full-cohort sex specific.

Table 5. Nested case–control study of the risk of stomach adenocarcinoma by calibrated intakes of total meat, red meat, poultry, and processed meat according to anatomic location among *Helicobacter pylori* antibody-positive and -negative subjects in the European Prospective Investigation Into Cancer and Nutrition (EPIC) cohort*

	H mylori antibody	No of control	Ca	se patients with stoma adenocarcinoma	ich	C	ase patients with gastr cardia adenocarcinoma	ic 1	:	Case patients with gastric noncardia adenocarcinoma		
Type of meat	status	subjects	No.	OR (95% CI)	P^{\dagger}	No.	OR (95% CI)	P^{\dagger}	No.	OR (95% CI)	P^{\dagger}	
Total meat	Negative	372	40	1.60 (0.26 to 9.96)	.76	22	3.03 (0.26 to 35.1)	.43	12	0.21 (0.001 to 38.0)	.14	
	Positive	769	201	2.57 (1.25 to 5.25)		47	0.52 (0.12 to 2.32)		113	5.32 (2.10 to 13.4)		
Red meat	Negative	372	40	1.78 (0.27 to 11.7)	.54	22	1.55 (0.10 to 24.5)	.20	12	1.22 (0.01 to 237)	.28	
	Positive	769	201	1.26 (0.69 to 2.32)		47	0.56 (0.16 to 2.00)		113	1.93 (0.90 to 4.12)		
Poultry	Negative	372	40	1.05 (0.56 to 1.98)	.71	22	1.22 (0.55 to 2.70)	.14	12	1.76 (0.34 to 9.19)	.79	
5	Positive	769	201	1.07 (0.84 to 1.36)		47	0.75 (0.46 to 1.22)		113	1.13 (0.80 to 1.60)		
Processed meat	Negative	372	40	0.45 (0.05 to 4.01)	.48	22	0.86 (0.03 to 27.0)	.42	12	0.002 (<0.001 to 62.6)	.25	
	Positive	769	201	2.00 (1.06 to 3.79)		47	1.62 (0.47 to 5.55)		113	2.67 (1.20 to 5.93)		

*Odds ratios (ORs) are for a daily intake increase of 100 g (total meat), 50 g (red and processed meat), or 10 g (poultry). Adjusted by sex, age at EPIC study entry, study center, date of blood extraction, height, weight, education level, tobacco smoking, cigarette smoking intensity, work and leisure physical activity, alcohol intake, energy intake, vegetable intake, and citrus and non-citrus fruit intake. Red meat, poultry, and processed meat intakes were mutually adjusted. CI = confidence interval.

[†]From two-sided likelihood ratio test for interaction with *H. pylori* infection status.

positive association between total meat intake (OR for a 100-g/ day increase in intake = 5.32; 95% CI = 2.10 to 13.4) and processed meat intake (OR for a 50-g/day increase in intake = 2.67; 95% CI = 1.20 to 5.93) and risk of gastric noncardia cancer in *H. pylori* antibody-positive subjects. There was no association between total and processed meat intake and gastric noncardia tumors in *H. pylori* antibody-negative subjects; however, the 95% confidence intervals were wide and the number of *H. pylori* antibody-negative case patients was low. Poultry intake was not associated with gastric noncardia cancer risk in *H. pylori* antibody-positive subjects. Tests for interaction were not statistically significant.

DISCUSSION

This is the largest cohort study to examine associations between intakes of fresh and processed meats and the incidence of cardia and gastric noncardia cancer in Western countries and the first study to examine intakes of these foods and risk of esophageal adenocarcinoma. This is also the first cohort study, to our knowledge, to explore modification of the effects of meat intake by H. pylori infection status. We observed positive and statistically significant associations between intakes of total, red, and processed meat and the risk of gastric noncardia cancer. All of these associations seemed to be restricted to the H. pylori-infected subjects. Furthermore, there was no association between poultry intake and the risk of gastric noncardia cancer. Cardia gastric cancer was not associated with meat intake of any type. We observed non-statistically significant positive associations between the risk of esophageal adenocarcinoma and intakes of total meat and processed meat and a potential association with poultry intake. In this study population, the absolute risk of development of gastric adenocarcinoma within 10 years for a study subject aged 60 years was 0.26% for the lowest quartile of total meat intake and 0.33% for the highest quartile of total meat intake.

The finding that *H. pylori* infection modifies the associations between total and processed meat intakes and the risk of gastric noncardia cancer may explain the different effect of meat intake between cardia and noncardia tumors. A meta-analysis of prospective studies found that cardia tumors are not associated with *H. pylori* infection (6). The mechanisms involved in the relationships among meat intake, *H. pylori* infection, and gastric cancer risk have yet to be fully elucidated. Red meat is an important source of iron, and it has been suggested that iron is an essential growth factor for *H. pylori* (32). However, other, unknown factors must play a role in the cancer risk because, although the intake of red meat has increased in most European countries during the last decades, the prevalence of *H. pylori* infection and the incidence of gastric noncardia cancer has decreased over the same period (3).

Few cohort studies have explored associations between meat and processed meat intakes and the risk of gastric cancer. With respect to fresh meat intake and gastric cancer risk, three cohort studies (14,15,33) observed no associations with total meat, beef, or pork intakes, whereas one study (16) found a weak but nonstatistically significant association. Processed meat (such as bacon or sausage) was statistically significantly and positively associated with gastric cancer in two cohort studies (15, 17) but not in three other studies (14,18,19). However, none of these studies distinguished between cardia and noncardia tumors. Results from case-control studies have also been inconsistent (13). Some studies (34,35) observed a statistically significant positive association between red meat intake and gastric cancer risk, whereas other studies (36-38) found a positive but nonstatistically significant association. However, the two largest studies (39,40) found no association between red meat intake and gastric cancer risk. With respect to esophageal cancer, the effect of meat and processed meat intake has never been analyzed in a cohort study for a Western population, and the evidence from case-control studies is limited and inconsistent (13).

Several plausible mechanisms have been suggested to explain the possible causal relationship between meat intake and cancer risk (41). These mechanisms involve potential effects of high levels of heme (a red organic pigment containing ferrous iron) in red meats, of fat and protein, of nitrite and nitrosamines, and of salt, as well as of heterocyclic amines and polycyclic aromatic hydrocarbons. One study (41) showed that red meat intake had a consistent dose response on the endogenous formation of *n*-nitroso compounds measured in fecal samples, whereas white meat intake had no effect. This effect seems to be associated with the content of heme, rather than with the content of protein or inorganic iron (42). Processed meat is a mixed category that consists mainly of pork and beef products and is an important source of salt, nitrites, and exogenous nitrosamines in the human diet (43). Nitrosamines have been shown to cause a wide range of tumors in more than 40 animal species and may be specifically involved in the etiology of gastric cancer and esophageal cancer (44), although so far, there is no conclusive epidemiologic evidence that these compounds are related to cancer risk in humans. Although the levels of sodium nitrite in foods have decreased during the last 20 years (43), it is still widely used as a food preservative in cured meat. Nitrites and nitrates can nitrosate amines and amides, thus forming potentially carcinogenic N-nitroso compounds (45). Nitrosating agents (46) are overproduced under chronic inflammatory conditions, a common step in the gastric precancerous process. In addition, salt is thought to induce an inflammatory process that leads to damage of the protective stomach mucosa (13). H. pylori infection may interact with salt, enhancing carcinogenesis after the gastric epithelium is damaged (13). It has also been suggested that the effect of salt on stomach inflammation could be stronger if nitrosamine compounds are involved (13).

Any effect of meat on cancer risk could be associated also with the content of heterocyclic amines and polycyclic aromatic hydrocarbons. Heterocyclic amines (47) and polycyclic aromatic hydrocarbons (48) are formed by cooking meat at a high temperature or over an open flame. We could not assess the associations of these chemicals with the risks of gastric cancer and esophageal adenocarcinoma because only some of the EPIC dietary questionnaires recorded detailed information about the method used to cook meat or the frequency of intake of more-well-done versus less-well-done meat or of browned meats. However, on the basis of the information obtained from the 24HR dietary recall, we know that the frequency of use of high-temperature cooking methods (i.e., grilling, frying, or barbecuing) varied from 15% in the EPIC cohort of Italy to 49% in the EPIC cohort of The Netherlands (49). Regarding our finding of a possible association between poultry intake and the risk of esophageal adenocarcinoma, we are not able to find an explanation. White meat (i.e., poultry) is not a source of the endogenous formation of N-nitroso compounds (41), and the frequency of use of high-temperature cooking methods for chicken in most of the EPIC countries was lower than 30%, although it varied from 8.3% in France to 88.3% in Germany (49).

Our study has several potential limitations. First, we did not collect information about family history of gastric cancer. However, a Japanese study (50) that was designed to assess the influence of this information observed no differences in lifestyle and risk factor patterns between gastric cancer patients with and without a family history of this disease. Second, our results could also be affected by measurement error in dietary intake, a common limitation of epidemiologic studies. The wide range of intakes of meat and processed meat reported in the EPIC study reduced, but did not eliminate, potential effects of measurement error. Because the magnitude of the distortion in the estimated relative risk depends on the ratio of the inter-individual variation to the intra-individual measurement error (51), regression dilution should have been lessened by the inclusion of a diverse range of intakes. In addition, our results for the association between meat intake and cancer risk were calibrated against a more detailed method of dietary assessment (the 24HR dietary recall). We have emphasized the results that were consistent in the original categorical and the continuous calibrated models and note that the study is based mostly in confirmed adenocarcinoma cases validated by a panel of pathologists.

In conclusion, despite the relatively low number of cardia and gastric noncardia cancer and esophageal adenocarcinoma cases in our study and the need for more cases and years of follow-up, our results suggest that meat intake is associated with the risk of gastric noncardia cancer and adenocarcinoma of the esophagus. We observed a statistically significant increase in gastric noncardia cancer risk associated with the intake of total, red, and processed meat. The associations with total and processed meat seemed to be restricted to *H. pylori* antibodypositive subjects. Cardia cancer was not associated with any type of meat intake. Given the low 5-year relative survival rates of European patients with gastric cancer or esophageal cancer (23% and 10%, respectively) (52), identification and better control of risk factors represent the most effective ways for reducing the burden of these tumors.

References

- (1) Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142–6.
- (2) Botterweck AA, Schouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645–54.
- (3) Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4–66.
- (4) El Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002;50:368–72.
- (5) Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 2002;132:34678–708.
- (6) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347–53.
- (7) Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004;96:388–96.
- (8) Gonzalez CA, Pera G, Agudo A, Palli D, Krogh V, Vineis P, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003;107:629–34.
- (9) Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349: 2241–52.
- (10) Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2002;98:241–56.
- (11) Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. Br J Cancer 2003;89:1672–85.
- (12) Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001;23: 72-81.
- (13) Potter J, editor. World Cancer Research Fund & American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: World Cancer Research Fund; 1997.
- (14) Ito LS, Inoue M, Tajima K, Yamamura Y, Kodera Y, Hirose K, et al. Dietary factors and the risk of gastric cancer among Japanese women: a comparison between the differentiated and non-differentiated subtypes. Ann Epidemiol 2003;13:24–31.
- (15) Ngoan LT, Mizoue T, Fujino Y, Tokui N, Yoshimura T. Dietary factors and stomach cancer mortality. Br J Cancer 2002;87:37–42.
- (16) Inoue M, Tajima K, Kobayashi S, Suzuki T, Matsuura A, Nakamura T, et al. Protective factor against progression from atrophic gastritis to gastric cancer—data from a cohort study in Japan. Int J Cancer 1996;66: 309–14.

- (17) Van den Brandt PA, Botterweck AA, Goldbohm RA. Salt intake, cured meat consumption, refrigerator use and stomach cancer incidence: a prospective cohort study (Netherlands). Cancer Causes Control 2003;14: 427–38.
- (18) McCullough ML, Robertson AS, Jacobs EJ, Chao A, Calle EE, Thun MJ. A prospective study of diet and stomach cancer mortality in United States men and women. Cancer Epidemiol Biomarkers Prev 2001;10:1201–5.
- (19) Galanis DJ, Kolonel LN, Lee J, Nomura A. Intakes of selected foods and beverages and the incidence of gastric cancer among the Japanese residents of Hawaii: a prospective study. Int J Epidemiol 1998;27:173–80.
- (20) Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113–24.
- (21) Linseisen J, Kesse E, Slimani N, Bueno-de-Mesquita HB, Ocke MC, Skeie G, et al. Meat consumption in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts: results from 24-hour dietary recalls. Public Health Nutr 2002;5:1243–58.
- (22) Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer 2004;4:206–15.
- (23) Margetts BM, Pietinen P. European Prospective Investigation into Cancer and Nutrition: validity studies on dietary assessment methods. Int J Epidemiol 1997;26:S1–5.
- (24) World Health Organization. International classification of diseases. 10th Revision (ICD-10). Geneva: WHO; 1992.
- (25) Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbio Immunol Scand 1965;64:31–49.
- (26) Ghiara P, Rossi M, Marchetti M, Di Tommaso A, Vindigni C, Ciampolini F, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997;65:4996–5002.
- (27) Slimani N, Kaaks R, Ferrari P, Casagrande C, Clavel-Chapelon F, Lotze G, et al. European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics. Public Health Nutr 2002;5:1125–45.
- (28) Ferrari P, Kaaks R, Fahey MT, Slimani N, Day NE, Pera G, et al. Within- and between-cohort variation in measured macronutrient intakes, taking account of measurement errors, in the European Prospective Investigation into Cancer and Nutrition study. Am J Epidemiol 2004;160: 814–22.
- (29) Rosner B, Gore R. Measurement error correction in nutritional epidemiology based on individual foods, with application to the relation of diet to breast cancer. Am J Epidemiol 2001;154:827–35.
- (30) Greenland S, Rothman KJ. Introduction to stratified analysis. In: Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1998. p. 53–79.
- (31) Ferrari P, Slimani N, Ciampi A, Trichopoulou A, Naska A, Lauria C, et al. Evaluation of under- and overreporting of energy intake in the 24-hour diet recalls in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002;5:1329–45.
- (32) Perez-Perez C, Israel D. Role of iron in Helicobacter pylori: its influence in outer membrane protein expression and in pathogenicity. Eur J Gastroenterol Hepatol 2000;12:1263–5.
- (33) Kneller RW, McLaughlin JK, Bjelke E, Schuman LM, Blot WJ, Wacholder S, et al. A cohort study of stomach cancer in a high-risk American population. Cancer 1991;68:672–8.
- (34) Correa P, Fontham E, Pickle LW, Chen V, Lin YP, Haenszel W. Dietary determinants of gastric cancer in south Louisiana inhabitants. J Natl Cancer Inst 1985;75:645–54.
- (35) Ward MH, Lopez-Carrillo L. Dietary factors and the risk of gastric cancer in Mexico City. Am J Epidemiol 1999;149:925–32.
- (36) Chen H, Ward MH, Graubard BI, Heineman EF, Markin RM, Potischman NA, et al. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr 2002;75:137–44.
- (37) Mathew A, Gangadharan P, Varghese C, Nair MK. Diet and stomach cancer: a case-control study in South India. Eur J Cancer Prev 2000;9: 89–97.
- (38) Zhang ZF, Kurtz RC, Yu GP, Sun M, Gargon N, Karpeh M Jr, et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer 1997;27:298–309.

- (39) Boeing H, Jedrychowski W, Wahrendorf J, Popiela T, Tobiasz-Adamczyk B, Kulig A. Dietary risk factors in intestinal and diffuse types of stomach cancer: a multicenter case–control study in Poland. Cancer Causes Control 1991;2:227–33.
- (40) Ji BT, Chow WH, Yang G, McLaughlin JK, Zheng W, Shu XO, et al. Dietary habits and stomach cancer in Shanghai, China. Int J Cancer 1998;76: 659–64.
- (41) Bingham SA, Hughes R, Cross AJ. Effect of white versus red meat on endogenous N-nitrosation the human colon and further evidence of a dose response. J Nutr 2002;132(11 Suppl):3522S–25S.
- (42) Cross AJ, Pollock JR, Bingham SA. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. Cancer Res 2003;63:2358–60.
- (43) Tricker AR. N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids. Eur J Cancer Prev 1997;6:226–68.
- (44) Mirvish SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 1995; 93:17–48.
- (45) Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutat Res 1991; 259:277–89.
- (46) Bartsch H, Spiegelhalder B. Environmental exposure to N-nitroso compounds (NNOC) and precursors: an overview. Eur J Cancer Prev 1996;5(Suppl 1):11–7.
- (47) Skog KI, Johansson MA, Jagerstad MI. Carcinogenic heterocyclic amines in model systems and cooked foods: a review on formation, occurrence and intake. Food Chem Toxicol 1998;36:879–96.
- (48) Phillips DH. Polycyclic aromatic hydrocarbons in the diet. Mutat Res 1999;443:139–47.
- (49) Rohrmann S, Linseisen J, Becker N, Norat T, Sinha R, Skeie G, et al. Cooking of meat and fish in Europe—results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur J Clin Nutr 2002;56:1216–30.
- (50) Huang XE, Tajima K, Hamajima N, Xiang J, Inoue M, Hirose K, et al. Comparison of lifestyle and risk factors among Japanese with and without gastric cancer family history. Int J Cancer 2000;86:421–4.
- (51) Day N, McKeown N, Wong M, Welch A, Bingham S. Epidemiological assessment of diet: a comparison of a 7-day diary with a food frequency questionnaire using urinary markers of nitrogen, potassium and sodium. Int J Epidemiol 2001;30:309–17.
- (52) Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Ann Oncol 2003;14(Suppl 5):v61–118.

Notes

We thank the members of the panel of pathologists for their valuable work: Dr. Roger Stenling, Umeå, Sweden; Dr. U. Mahlke, Postdam, Germany; Dr. Hendrik Bläker, Heidelberg, Germany; Dr. Vicki Save, Cambridge, United Kingdom; Dr. Claus Fenger, Copenhagen, Denmark; Dr. Julio Torrado, San Sebastian, Spain; Dr. Johan Offerhaus, Amsterdam, The Netherlands. We also thank Cátia Moutinho, Porto, Portugal, for her excellent technical support to the panel of pathologists.

Specific study results of the nested case–control study within EPIC (EUR-GAST) were obtained with financial support from the FP5 of European Commission (QLG1-CT-2001-01049).

The EPIC study was funded by "Europe Against Cancer" Programme of the European Commission (SANCO); Ligue contre le Cancer (France); Société 3M (France); Mutuelle Générale de l'Education Nationale; Institut National de la Santé et de la Recherche Médicale (INSERM); German Cancer Aid; German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health (RCESP-C03/09; RTICCC-C03/10); the participating regional governments and institutions of Spain; Cancer Research UK; Medical Research Council, United Kingdom; the Stroke Association, United Kingdom; British Heart Foundation; Department of Health, United Kingdom; Greek

Ministry of Health; Greek Ministry of Education; Italian Association for Research on Cancer; Italian National Research Council; Dutch Ministry of Public Health, Welfare and Sports; Dutch Ministry of Health; Dutch Prevention Funds; LK Research Funds; Dutch ZON (Zorg Onderzoek Nederland); World Cancer Research Fund (WCRF); Swedish Cancer Society; Swedish Scientific Council; Regional Government of Skane, Sweden; and Norwegian Cancer Society. The study sponsors had no role in the design, collection, analysis or interpretation of the data, nor in writing or submitting the manuscript.

Present address: E. Riboli, Department of Epidemiology and Public Health, Imperial College, London, United Kingdom.

Manuscript received July 18, 2005; revised December 20, 2005; accepted January 9, 2006.